Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) presented new clinical data from the ABILITY-1 study of MDNA11 at the inaugural AACR Immuno-Oncology Conference. The study evaluates MDNA11 alone or combined with Merck's KEYTRUDA® in advanced solid tumors.
Key highlights include MDNA11's ability to significantly expand 'stem-like' CD8+ T cells, which are associated with more persistent anti-tumor activity. In the monotherapy dose expansion cohort, MDNA11 showed a 30% objective response rate in checkpoint-resistant patients. The combination with KEYTRUDA® demonstrated a 78% disease control rate, including one complete response, one partial response, and five stable disease cases.
The Safety Review Committee cleared the 120 µg/kg MDNA11 dose every two weeks in combination with KEYTRUDA®, with no dose-limiting toxicities observed. The company is also exploring dosing every three weeks for improved patient convenience. Additional tumor types will be evaluated, with combination dose expansion expected to begin mid-2025.
Medicenna Therapeutics (OTCQX: MDNAF) reported its Q3 FY2025 financial results and operational updates. Key highlights include a 78% disease control rate in the MDNA11-KEYTRUDA combination arm and a 30% objective response rate in the monotherapy dose expansion cohort. The company maintained a strong financial position with $30 million in cash, expected to fund operations through mid-2026.
The ABILITY-1 trial showed promising results, including one complete response in a 70-year-old patient with advanced anal cancer and one partial response in a colorectal cancer patient. R&D expenses increased to $3.4 million from $3.0 million year-over-year, while G&A expenses slightly decreased to $1.7 million. The company reported a quarterly net loss of $5.2 million ($0.07 per share).
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in two major healthcare investor conferences in February 2025. The company will present at the Oppenheimer Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 9:20 a.m. ET, with a webcast available for 180 days following the event.
Additionally, Medicenna will participate in a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference on Friday, February 28, 2025, in New York City. The company's management team will be available for one-on-one meetings with investors during both conferences. Interested investors can schedule meetings through conference representatives or by contacting Medicenna's investor relations team directly.
Medicenna Therapeutics (MDNAF) presented new preclinical data for MDNA11 at the 2024 San Antonio Breast Cancer Symposium. The data showed that single-agent MDNA11 outperformed combined immune checkpoint inhibitors in preventing metastasis and achieving long-term survival in triple negative breast cancer (TNBC) models.
Key findings demonstrated that a single low dose of MDNA11 as neoadjuvant therapy significantly prevented metastasis, with 6/7 mice at low-dose (2 mg/kg) and 7/8 mice at high-dose (5 mg/kg) surviving over 4 months without metastasis signs. The treatment also enabled memory immune response against tumor rechallenges, while promoting CD8+ T cell infiltration into the tumor microenvironment without affecting Treg cells.
Medicenna Therapeutics announced updated clinical data from its Phase 1/2 ABILITY-1 study, highlighting significant progress in cancer treatment. A notable achievement includes the first complete response (CR) in a 70-year-old patient with advanced anal cancer within 8 weeks of treatment combining MDNA11 with KEYTRUDA®.
The study demonstrates promising disease control rates of 55% in monotherapy and 78% in combination arms. Key findings include durable complete regression in two CPI-resistant patients, with one melanoma patient remaining tumor-free at week 63 and a pancreatic cancer patient maintaining response for 11 months post-study.
Safety profile shows over 90% of treatment-related adverse events were Grade 1-2 and transient. Additional clinical data will be presented at medical conferences in Q1 and Q2 of 2025.
Medicenna Therapeutics announced it will present updated clinical data from its ongoing Phase 1/2 ABILITY-1 study at the 2024 Immunotherapy Bridge Conference in Naples, Italy. The presentation will showcase results from both monotherapy and combination arms evaluating MDNA11, a long-acting 'beta-enhanced not-alpha' interleukin-2 super-agonist, in patients with advanced or metastatic solid tumors. Dr. Arash Yavari will deliver the presentation on December 5, 2024, focusing on safety and efficacy results from this first-in-human study.
Medicenna Therapeutics presented preclinical data on MDNA11 and bizaxofusp at the 2024 SNO Annual Meeting. The data showed significant results in treating glioblastoma (GBM). MDNA11, a long-acting IL-2 Superkine, demonstrated survival benefits and enhanced immune cell expansion, while bizaxofusp selectively targeted tumor cells and immune-suppressive cells. The combination therapy showed synergistic tumor-killing effects in GBM tumoroids. Key findings included MDNA11's significant survival benefit (p = 0.031) in GBM models and bizaxofusp's selective elimination of Tregs (IC50 = 0.011 nM). The results suggest potential breakthrough treatment for cancers not responding to current immunotherapies.
Medicenna Therapeutics reported Q2 fiscal 2025 results highlighting strong performance of MDNA11 in the ABILITY-1 study. The drug showed a 30% objective response rate in monotherapy dose expansion and demonstrated effectiveness against ICI-resistant cancers. Notable results include 66.7% response rate in MSI-H patients with pancreatic cancer. The company reported $30.4 million in cash and equivalents, with an additional $1.9 million from warrant exercises, extending runway through mid-2026. The study's combination with KEYTRUDA® showed favorable safety profile with no dose-limiting toxicities at 90 µg/kg dose.
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) has announced upcoming presentations at two major medical conferences. At the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) in Houston (November 21-24, 2024), the company will present pre-clinical data on MDNA11 and IL-2 Superkines in glioblastoma models.
Additionally, at the 2024 San Antonio Breast Cancer Symposium (SABCS) (December 10-13, 2024), Medicenna will present pre-clinical data on MDNA11's effectiveness as a neoadjuvant treatment in aggressive metastatic breast cancer models. Both presentations will focus on the company's innovative immunotherapy approaches using Superkines.
Medicenna reported positive results from its Phase 1/2 ABILITY-1 study of MDNA11, showing a 30% objective response rate in monotherapy dose expansion cohort among advanced solid tumor patients who failed immune checkpoint inhibitor therapy. Among phase 2-eligible patients, the response rate was 25%, including 1 complete response and 4 partial responses. The drug demonstrated encouraging safety profile in combination with KEYTRUDA®, with no dose limiting toxicities observed. Notable responses included 2 partial responses in MSI-H pancreatic cancer patients and tumor control in 4 out of 5 evaluable patients in the combination arm, including a partial response in MSS colon cancer.